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Summary: We propose a novel response-adaptive randomisation procedure for multi-armed trials with normally
distributed outcomes which is non-myopic, thus is near-optimal in terms of patient benefit, yet maintains computa-
tional feasibility. We derive our response-adaptive algorithm based on the Gittins index for the multi-armed bandit
problem, as an extension of the method first introduced in Villar et al (2015). We illustrate the proposed procedure
by simulations in the context of Phase II cancer trials. Our results show that there are efficiency and patient benefit
gains of using a response-adaptive allocation procedure with a continuous endpoint instead of a binary one. These
gains persist even if an anticipated low rate of missing data due to deaths, drop-outs or complete responses is imputed
online through a procedure introduced in this paper. Additionally, we discuss how there are response-adaptive designs
that outperform the traditional equal randomised design both in terms of efficiency and patient benefit measures in
the multi-armed trial context.
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1. Introduction
Response-adaptive randomisation (RAR) has been widely developed ever since the idea
was first suggested by Thompson (1933) (Hu and Rosenberger, 2006). The most common
motivation behind such procedures is to achieve a patient benefit objective, i.e. to reduce
exposure to inferior treatments by skewing the allocation towards superior treatments based
on observed responses of previous patients. Incorporating such an objective into a trial design
is particularly important when the disease under study is rare - in which case a substantial
proportion of patients in the population will be included in the trial - and when an inferior
treatment could result in a fatal outcome.
Despite the vast extent of RAR procedures proposed in the literature, most of them assume:
(i) binary responses; (ii) are defined for trials with only two treatments and (iii) are myopic,
thus not globally optimal. However, many recent clinical trials have continuous primary
outcomes and include more than two arms. Wason and Trippa (2014) report that 39% of all
multi-arm clinical trials published in four major medical journals during 2012 had normally
distributed primary outcomes. Most RAR procedures are not easily extended from binary to
continuous responses, particularly those based on urn models (Atkinson and Biswas, 2013),
nor are they defined for the multi-armed case and this considerably limits their use in practice.
Moreover, this “shortage of RAR methodology to handle cases with multiple treatments”
(Zhang et al, 2011) persists despite the fact that RAR has the greatest potential for efficiency
and patient benefit gains in multi-armed trials (Berry, 2010). A few RAR procedures for
continuous outcomes have been proposed in the literature and a detailed review of these,
along with examples of real trials using continuous outcomes, can be found in Chapter 4 of
Atkinson and Biswas (2013) and Biswas and Bhattacharya (2016).
Further, almost all RAR procedures proposed in the literature (for binary or continuous
outcomes) use only past observations (allocations and responses) to influence the decision
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for the next patient, without considering the number of patients remaining to be treated
(inside or outside of the trial) or the information they could provide. It is well-known that
such myopic strategies are not globally optimal in general (Villar et al, 2015). The globally
optimal approach is based on the multi-armed bandit problem (MABP) which considers all
possible sequences of trial observations, and the sequence that maximises patient response
is selected. As a result, the traditional approach to solve the MABP based on dynamic
programming is much more computationally intensive than alternative myopic procedures,
which is the predominant reason why myopic approaches have been favoured in the RAR
literature. Some recent work proposing non-myopic RAR procedures for binary responses
based on bandit-based solutions includes Villar and Rosenberger (2018), Williamson et al
(2017) and Villar et al (2015). We will refer to such procedures as “forward-looking”, rather
than non-myopic, to be consistent with the terminology used in previous papers.
Within the bandit literature, the case of continuous endpoints has received more attention
and several forward-looking adaptive allocation rules have been proposed. Examples relevant
to this paper include Coad (1991), Wang (1991) and Smith and Villar (2017), all of which
use the Gittins index for normally distributed outcomes. However, the main limitation of
these designs from a clinical trials perspective is their deterministic nature. Randomisation is
essential in order to remove various sources of bias and it additionally provides a probabilistic
basis for inference (Rosenberger and Lachin , 2015).
Motivated by the above considerations, we propose a novel bandit-based allocation rule
that: (i) applies to continuous outcomes, assumed to be normally distributed; (ii) is defined
for multi-armed trials; (iii) is forward-looking, thus is near-optimal with respect to patient
response; (iv) is computationally feasible, and (v) is randomised. Additionally, we investigate
the impact on patient benefit of dichotomising a continuous endpoint, which is a widely
adopted approach in clinical research that has received considerable attention in the literature
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(Royston et al , 2006). A very common reason for this practice is to deal with complete
responses and missing data (due to death or drop-out, for example) since these naturally
fall into success and failure categories, respectively. However, dichotomisation comes at an
efficiency cost (either a reduced power level or larger sample size) (Lavin, 1981; Wason et al,
2011), as well as raising other issues.
Dealing with complete responses and missing data poses an extra challenge that is exclusive
to the implementation of RAR in a trial. The imputation method suggested in Karrison et
al (2007), which is the only one that has shown moderate uptake in practice (Wason and
Jaki, 2016), inputs unobserved responses using the distribution of data collected at the end
of the trial and therefore, the imputed data cannot be used to perform any adaptations. In
this paper, we suggest a simple modification of Karrison’s procedure that deals with missing
data for a continuous endpoint in an online fashion, which in turn allows for the use of RAR
to allocate patients dynamically during the trial.
In Section 2, we introduce the extension of the FLGI rule for normally distributed endpoints
and present a simple example to illustrate its implementation. In Section 3, we compare our
novel response-adaptive procedure to alternative procedures through extensive simulation
studies in the context of a real Phase II cancer trial. We discuss the patient benefit and
efficiency cost of artificially dichotomising a continuous endpoint in Section 4 and suggest
how our method can be implemented to accommodate missing data due to deaths, drop-outs
and complete responses in Section 5. We draw conclusions in Section 6.
2. The Forward-Looking Gittins Index Rule for Normally Distributed
Endpoints
In this section, we define a response-adaptive procedure for normally distributed endpoints
based on an extension of the Forward-Looking Gittins Index (FLGI) proposed in Villar et
al (2015) for binary endpoints. We consider a multi-armed clinical trial that will test the
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effectiveness of K experimental treatments against a control treatment on a sample of T
patients, with K and T fixed. Patients are labelled by t (t = 1, . . . , T ) and treatments by
k (k = 0, . . . , K), where k = 0 denotes the control. The response of patient t allocated to
arm k is a random variable denoted by Yk,t and assumed to follow a normal distribution
Yk,t ∼ N(µk, σ2k). For simplicity, we also assume that a larger response is desired and that
σ2k is known. We will discuss how to relax these two assumptions in Section 3 and Section 6,
respectively.
In order to derive a FLGI rule, we first need to obtain the Gittins index and the MABP
associated to this trial design problem. For this purpose, we assume the following. (i) Each
unknown parameter µk has a prior distribution pik,0 at the start of the trial, i.e. before
any observation has been made. Under the usual equipoise assumption, we will let pik,0
be the improper uniform prior over the real line. This allows us to isolate the effects on
patient response and other relevant statistical properties of the bandit-based design alone
without using prior (historical) data. (ii) Patients enter the trial one-by-one and responses are
observed immediately after treatment. We will remove this assumption when we define the
FLGI rule. (iii) Prior distributions are converted into normal posterior distributions for each
µk via Bayes’ Theorem given the conjugacy of the prior and normally distributed responses.
After treating patient t, if nk,t responses from treatment k have been observed (each denoted
by yk,i with i = (1, . . . , nk,t) and nk,t 6 t), then the posterior distribution of µk at time t
is pik,t(µk|yk,1, . . . , yk,nk,t) ∼ N
(
,
σ2k
nk,t+1
)
by Bayes’ Theorem, where yk,t =
1
nk,t
∑nk,t
i=1 yk,i is
the sample mean. (iv) Only one treatment can be allocated per patient and we let ark,t be
a binary indicator variable denoting whether patient t + 1 is assigned to treatment k for
patient allocation rule r, given the information available on all treatments (as summarised
by the pik,t prior distributions).
The MABP is to find a patient allocation rule r that attains the maximum expected
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patients’ response given the initial information about the treatments before the start of the
trial. Mathematically, this is expressed as:
max
r∈R
Er
[(
T−1∑
t=0
K∑
k=0
dtE[Yk,t|xk,t]ark,t
)∣∣∣x˜0] , (1)
where xk,t = (yk,t, nk,t), x˜0 = (xk,0)
K
k=0 is the initial joint state with all the prior parameters,
Er[·] denotes expectation under allocation rule r, and d is a discount factor (i.e. 0 6 d < 1).
In MABPs, rewards are geometrically discounted so that T = ∞ can be considered, i.e.
patient t’s response yields a reward of dtYk,t for some k. In practice, a solution that depends
on d, such as the Gittins index, can be adapted to solve an undiscounted problem with a
specific finite horizon, as explained in Edwards et al (2017) (Definition 6.6).
The exact solution to (1) via dynamic programming uses a backward induction algorithm
which becomes computationally infeasible very quickly as T and K grow. The Gittins
index solution, first introduced by Gittins and Jones (1979), eliminates this computational
infeasibility by ensuring the optimal solution to (1) can be obtained by simply allocating
every patient to the arm with the highest Gittins index. As explained in Gittins et al (2011),
for (1), the Gittins indices G(yk,t, nk,t, σk, d) can be written as
G(yk,t, nk,t, σk, d) = yk,t + σkG(0, nk,t; 1, d), (2)
where G(0, nk,t, 1, d) denotes the Gittins index value of a standardised bandit problem with
sample mean 0, variance 1 and nk,t− 1 observations. Notice that nk,t = 1 represents the case
of no observations and a flat prior. These were first computed in Jones (1975). Note that
analogous indices exist for the case of an unknown variance (Gittins et al, 2011, Table 8.3).
As in Smith and Villar (2017), we implement the solution in (2) at a very low computational
cost by calculating the values of G(0, nk,t, 1, d) in advance and interpolating from the tables
printed in Gittins et al (2011), pp. 261-262. Details on how to compute these indices using
value iteration can be found in Chapters 7 and 8 of Gittins et al (2011).
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Using (2) and the Gittins index rule, we can compute the FLGI probabilities for the case
of a normally distributed endpoint (with a known variance) using equation (3) in Villar et al
(2015). We now assume that instead of enrolling patients one-by-one, patients are enrolled in
groups of size b over J stages, so that J×b = T . Our response-adaptive rule will sequentially
randomise the next b patients among the K + 1 treatments at stage j (j = 1, . . . , J) given
the data up to and including block j − 1 according to what the Gittins index rule would do.
To illustrate the rule’s implementation, we calculate the FLGI probabilities using the
simplest possible case of a two-arm trial testing a control treatment (k = 0) against an
experimental treatment (k = 1) with a block of size two (b = 2) and a known, common
variance of σ2k = σ
2 = 1. We assume that µk follows an improper uniform distribution over
the real line at the start of the trial for both k = {0, 1}. Suppose further that both patients
are allocated to the control treatment in the first block of the trial resulting in responses
y0,1 and y0,2 with a sample mean of y0,2 = −0.1. Thus, the two relevant parameters in order
to obtain the corresponding Gittins index for the control treatment are y0,2 = −0.1 and
n0,2 = 3. Consequently, for the second block, the prior parameters for each treatment are
x˜2 = [(−0.1, 3); (0, 1)], i.e. µ0 ∼ N(−0.1, 13) and µ1 ∼ U(−∞,∞).
From equation (2), setting d = 0.995 and using the tables in Gittins et al (2011), the
Gittins index for the control treatment is G0(−0.1, 3, 1, 0.995) = −0.1 + 0.20137
3(1−0.995) 12
= 0.8493.
For the experimental treatment, we only have the information available from the initial prior
which corresponds to y1,2 = 0 and n1,2 = 1. Thus, G1(0, 1, 1, 0.995) = 0 +
0.12852
(1−0.995) 12
= 1.8175.
Figure 1 illustrates how the FLGI probabilities for block two, given the data in block
one, are computed via a probability tree. Given that the experimental treatment has the
maximum Gittins index, the first patient of the second block is allocated to the experimental
treatment with probability (w.p.) 1 since there is only one optimal action possible at this
point. When the second patient of the second block is to be allocated, we need to have
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observed the (random) outcome of the first patient in this block, denoted by Y1,3, in order
to update the indices and determine the optimal action. The updated parameters for the
experimental treatment, as a function of the observed information on this treatment and
given the previous optimal action, are y1,3 =
0+Y1,3
2
and n1,3 = 2. Thus, the corresponding
index for the experimental treatment can also be expressed as a function of the random
outcome from patient one in the second block as follows: G1(Y 1,3, n1,3, 1, 0.995) =
Y1,3
2
+
G1(0, 2, 1, 0.995) =
Y1,3
2
+ 1.2157.
For the control treatment, we have no new information and so the corresponding index
remains unchanged at G0(Y 0,3, n0,3, 1, 0.995) = 0.8493. According to the Gittins index rule,
it will be optimal to allocate the experimental treatment to the second patient in the block
if G1(Y 1,3, n1,3, 1, 0.995) > G0(Y 0,3, n0,3, 1, 0.995) = 0.8493, that is, if Y1,3 > −0.7328 (from
(2)). Since Y1,3 is a normally distributed random variable, we expect this to happen w.p.
0.7682, i.e. P (Y1,3 > −0.7328) = 0.7682. If Y1,3 < −0.7328, which happens w.p. 0.2318, then
G1(Y 1,3, n1,3, 1, 0.995) < G0(Y 0,3, n0,3, 1, 0.995) and the second patient in the second block is
optimally allocated to the control treatment. Notice that if Y1,3 = −0.7328, then there is
a tie in the index values and it is equally optimal to allocate any of the two treatments in
that case. In theory, since we are dealing with a continuous distribution, this would happen
w.p. 0. However, in practice, this is possible and if it were to happen, we would simply
randomise w.p. 0.5. Hence, the probability of a patient receiving the experimental treatment
when using the normal FLGI procedure in this block is 1+1×P (Y1,3>−0.7328)
2
= 0.8841, and
0+1×P (Y1,3<−0.7328)
2
= 0.1159 for the control treatment.
[Figure 1 about here.]
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3. Simulation Study
3.1 Alternative Designs & Operating Characteristics
Next, we will report simulations that compare the FLGI for a normally distributed endpoint
against the following existing randomisation procedures:
(1) Equal Randomisation (ER), where each patient is randomly allocated to one of the K+1
arms with equal probability, 1/(K + 1). This is the predominant mode of randomisation in
practice, thus it will be used as a reference to compare all designs.
(2) Modified Zhang and Rosenberger (MZR) is a RAR procedure for continuous outcomes
based on the formulation by Zhang et al (2006) which was later modified by Biswas (2009)
to allow for a response distribution with a negative mean. The rule aims at an optimal
allocation proportion, ρ∗, which in this case minimises the total of inverse mean responses,
i.e. n0/µ0 + n1/µ1. This design results in an optimal allocation proportion shown below:
ρ∗ =

c if {µ0, µ1 > 0 and ρc < c} or
{
µ0, µ1 < 0,
σ0
σ1
>
√
µ1
µ0
}
or {µ0 < 0, µ1 > 0} ,
ρc if {µ0, µ1 > 0, c 6 ρc 6 1− c} ,
1− c if {µ0, µ1 > 0, ρc > 1− c} or
{
µ0, µ1 < 0,
σ0
σ1
<
√
µ1
µ0
}
or {µ0 > 0, µ1 < 0} ,
where ρc =
σ0
√
µ0
σ0
√
µ0+σ1
√
µ1
and c ∈ [0, 1
2
]
.
In practice, estimates of the unknown parameters µ0 and µ1 are sequentially updated
and substituted into the expression for ρ∗ based on the current data available. The initial
parameter estimates require some data to be available before the RAR procedure can be
applied which is achieved by allocating the first nER patients using ER.
(3) Constrained Gittins Index Rule (CGI) which was proposed by Wang (1991) and further
studied by Coad (1991), is an allocation rule also based on the Gittins indices. However,
unlike the FLGI, this design is not implemented in terms of probabilities, and hence is not
strictly randomised as RAR rules are. This is a limitation in practice and explains why
CGI has been neglected as a comparator within the RAR literature. The rule is defined as
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follows: if nc0,t < n1,t, allocate the next patient to treatment 0; if n
c
1,t < n0,t, allocate the next
patient to treatment 1; else, allocate the next patient to the treatment which currently has
the largest Gittins index (randomising if they are equal). The parameter c > 1 is a tuning
parameter in which c = 1 corresponds to ER whilst c → ∞ eventually recovers the Gittins
index. Following Wang (1991), we fix c = 2 in our simulations.
(4) Thompson Sampling (TS) randomises patients to arms based on their posterior probabil-
ity of being the “best” arm. Specifically, we consider a slightly modified version of Thompson
(1933), suggested by Thall and Wathen (2007), where the probability of allocating treatment
k to patients in block j is proportional to the posterior probability that µk is the largest
current expected response, which is given by:
Pr(maxi µi=µk|x˜(j−1)b)
c∑K
k=0 Pr(maxi µi=µk|x˜(j−1)b)
c , where c =
(j)b
2T
is a
tuning parameter that recovers ER when c = 0 and TS when c = 1.
(5) Trippa et al. Procedure (TP) randomises patients proportional to the posterior prob-
abilities of each experimental arm being better than the control arm given the observed
data, but it also protects the allocation to the control arm. In this paper, we have used the
implementation of Trippa et al (2012) that is analogous that of Table 2 in Villar et al (2015).
(6)Controlled FLGI (CFLGI) is a variant of the FLGI design proposed in Villar et al (2015)
which, similarly to the TP, protects the allocation to the control arm by ensuring that the
corresponding allocation probability is always at least 1/(K + 1).
Note that both (2) and (3) are fully sequential and only defined for the two-armed case
whilst (5) and (6) apply only to the multi-armed case. For all the rules which require the
specification of a prior distribution on each µk, we will take that to be the improper uniform
distribution over the real line, as with the FLGI designs. Note that rule (2) is not Bayesian
but requires an initial burn-in phase of ER to obtain initial parameter estimates. For the
index based designs, a discount factor of d = 0.995 is used in all of the simulations, and
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the allocation probabilities defined in the FLGI designs, TS and TP are computed using a
Monte-Carlo approximation based on 100 replicas.
To evaluate the performance of all designs, we consider patient benefit and usual inferential
measures. The former includes two measures: (i) the expected proportion of patients in
the trial allocated to the superior treatment, E(p∗), and (ii) the expected total response
(ETR) during the trial, which for ease of interpretation is reported as a perceptual change
attained for rule r with respect to the theoretical ETR for ER, computed as (ETRr −
ETRER)/ETRER × 100 and denoted by ETO%. For the inferential measures, we focus on
standard operating characteristics, including: power, 1 − β; type I error rate, α; and bias
in the maximum likelihood estimate of the treatment effect, E(∆ˆ − ∆), with ∆ = µk − µ0
and ∆ˆ = (µˆk − µˆ0). For the multi-armed case, we report both the marginal power and bias
for the best experimental arm under the alternative hypothesis. Under the null hypothesis,
when there is no best experimental arm, we take it to be the control arm.
We consider the following hypotheses: H0 : µ0 = µk∀ k versus the one-sided alternatives,
H1,k : µ0 < µk for some k > 0 considered the best arm. These will be tested using the
following test statistic Zk =
Y¯k−Y¯0√
σk
nk
+
σ0
n0
for k = 1, . . . , K, where nk is the total number of
observations from arm k and Y¯k is the sample mean of arm k at the end of the trial. In the
two-armed case, this is the standard z-test. However, in the multi-armed case, we consider
the joint distribution of Z1, . . . , ZK and use a critical value, z1−α, to achieve a family-wise
type I error rate (FWER) close to the specified α, where FWER is defined as the probability
of obtaining at least one false positive within the family of hypotheses. We use a simulation-
based approach to control the FWER, as explained in Smith and Villar (2017).
3.2 A Two-armed Trial
To motivate the two-armed setting, we use the example provided by Karrison et al (2007) for
a two-armed Phase II cancer trial in which the primary endpoint is the change in tumour size
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from baseline to the time of follow-up for patient t under treatment k, denoted by Ck,t, and is
naturally a continuous variable. After a log-transformation, Ck,t is approximately normally
distributed, as shown by Lavin (1981). Under the assumption that Y0,t = − log(C0,t) ∼
N(0.155, 0.642) and Y1,t = − log(C1,t) ∼ N(0.529, 0.642), the total sample size required to
detect this treatment difference with approximately 80% power at the α = 0.05 significance
level when using a normal endpoint and assuming complete observations is T = 72. Note
that in order to deal with the fact that a smaller tumour size is a desirable outcome, we have
added a minus sign and transform the endpoint into tumour reduction rather than tumour
change.
Results
Table 1 displays the results from 10000 replications of the trial. As expected, under the
null hypothesis all the designs are equal in terms of patient benefit (ETO% and E(p∗)). All
designs allocate the same proportion of patients to each treatment on average (close to 0.50).
The main difference between designs under the null is the variability level in the expected
allocations, represented by the standard deviations (s.d.) of E(p∗), with FR and FLGI (for
b = 1) being the least and most variable, respectively. As the block size, b, increases, the
FLGI becomes less variable since the allocation probabilities are based on more observed
data. Relative to the non-index based designs, the Constrained GI design also has a large
variability which is comparable to that exhibited by the FLGI when b = 6. The allocations
under the index based procedures tend to be more variable because they aim at maximising
patient response. For the MZR design, we use a range of different sizes for the initial ER
period, nER, to show the effect it has on the performance and observe that the variability in
the allocations decrease as the size of nER increases. In terms of the bias of the treatment
effect estimator, all are (on average) unbiased under H0. Note that we have used adjusted
z-critical values to control type I error rates for all designs following the approach used in
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Smith and Villar (2017). The (unreported) type I error inflation incurred for the the FLGI
when using the 95th percentile of the standard normal distribution as the critical value, i.e.
z0.95 = 1.645, is approximately 11% for b = 1 and it decreases as the block size grows, as
expected. A similar level and pattern of inflation occurs for TS.
The results under H1, in which the experimental treatment (k = 1) is the truly best arm
and we are testing for superiority, show more contrasts among designs. First, we focus on the
FLGI design and in particular, the effect of varying the block size, b, on the power/patient
response trade-off. Note that when b = 1, the FLGI design is statistically identical to the fully
sequential Gittins index rule and so favours patient response. At the other extreme, when
b = T (so that J = 1), the FLGI design is equivalent to ER and therefore favours power.
Thus, consistent with the findings in Villar et al (2015) for the binary case, Table 1 shows
that as b increases under H1, the patient benefit measures (and corresponding standard
deviations) decrease, whilst the power increases (at a faster rate) which perfectly illustrates
the natural tension between these two conflicting goals. This relationship is depicted visually
in Figure 2 for T = 128.
In terms of the patient benefit measures, the index based designs (namely the FLGI and
Constrained GI) perform the best out of all the designs considered. Relative to ER, for a
moderate block size of b = 9, the FLGI allocates approximately 35% more patients to the
superior treatment (equivalent to 25 patients) which is an impressively large improvement.
Moreover, the expected total tumour size reduction is nearly 38% greater than that obtained
when using ER. Even for a large block size of b = 36, the FLGI allocates approximately 21%
more patients to the experimental treatment and achieves an expected total tumour size
reduction 23% larger than ER. All other block sizes for the FLGI have a total tumour size
reduction at least 30% greater than ER, on average. The Constrained GI is shown to perform
similarly to the FLGI when b = 12. TS has a total tumour size reduction rate of at least
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20% relative to ER for small and moderate b, on average, whereas MZR falls below this for
all b.
As mentioned above, the cost of these patient benefit gains is a severe reduction in the
power compared to that of ER. However, this is ameliorated as b increases. Although both
MZR and TS do not perform as well as the index based designs with respect to the patient
benefit measures, they do outperform them in terms of power for all block sizes. The ER
design attains an essentially unbiased treatment effect estimator, as expected, with the largest
relative bias exhibited by the FLGI design when b = 1 (or equivalently, the GI design),
which is expected as this is the design with the biggest imbalance between the two arms,
and with the smallest number of observations on the control (inferior) arm. As a result, µˆ0
will be substantially underestimated thus giving rise an overestimated ∆ˆ (and positive bias
of treatment effect). As b increases, and consequently the number of observations on the
control arm increases, the bias (and associated standard deviations) of the treatment effect
estimator decreases.
These results emphasise the very important point that, in a two-armed setting, none of
the designs are uniformly better than the others for every performance measure since each
design is tailored towards a different objective. This makes direct comparisons between such
designs infeasible.
[Table 1 about here.]
[Figure 2 about here.]
3.3 A Multi-armed Trial
To demonstrate the performance of the normal FLGI in the multi-armed setting, we use the
Phase II cancer trial setting described in Karrison et al (2007) as a case study. The objective
of this study is to compare the effects of using erlotinib in combination with different doses
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of sorafenib, as opposed to using erlotinib alone, in patients with non-small-cell lung cancer.
The primary endpoint is again the change in tumour size from baseline to eight weeks.
Patients were randomly assigned to one of three treatment arms: 150 mg of erlotinib plus
placebo; 150 mg of erlotinib plus 200 mg of sorafenib; or 150 mg of erlotinib plus 400 mg
of sorafenib. For simplicity, we will refer to these three arms as the control, low-dose and
high-dose, respectively.
Based on data from four previous trials, the log ratio of tumour sizes is assumed to have
a mean of 0.05 for the control, -0.07 for the low-dose and -0.13 for the high-dose with a
common standard deviation of 0.346. We will therefore assume that Y0,t ∼ N(−0.05, 0.3462),
Y1,t ∼ N(0.07, 0.3462) and Y2,t ∼ N(0.13, 0.3462) for the control arm, low-dose and high-dose,
respectively. We simulate a trial of size T = 120, which should have at least 80% power using
a one-sided test at the α = 0.10 when no correction for multiplicity is considered. In our
simulations, we will ensure a one-sided test at the α = 0.10 FWER level, and since we adjust
for multiplicity, the power will fall slightly below 80%, illustrating the effect of correcting for
multiplicity on power.
Results
Under the null, the only relevant difference among designs is the variability of resulting
allocations, with the rules performing the best in terms of patient benefit being the most
variable ones. These results are omitted from the main text of the paper but are provided in
full in a table of the Web Appendix. Results for the multi-armed case under the alternative
hypothesis are summarised in Figure 3 and are also included in full in the Web Appendix.
Figure 3 shows a star plot for each design (with blocks 1, 15, 40 and 60) against power,
expected proportion of patients allocated to the superior arm, average bias of the treatment
effect estimator and variability of the allocation. The most desirable values lie towards the
outer edge of the star plot with the least favourable values towards the centre. Figure 3
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summarises the key features of each design showing that ER performs very well with respect
to power, average bias and variability but poorly with respect to patient benefit for all block
sizes, whilst in contrast the FLGI design performs poorly with respect to power, average bias
and variability but the best with respect to patient benefit. The CFLGI and TS design, on
the other hand, have values lying near to the outer edge of the star plot for all measures,
thus showing that they perform well with respect to all of the performance measures. With
the exception of the fully sequential case (b = 1), TS and CFLGI have similar performances
but are not easily comparable as they attain different compromises between the competing
objectives. Rather than having a flat probability protection for the control arm during the
trial, the definition of the CFLGI rule could be adjusted in a similar way to TS and TP.
By doing that, we expect the CFLGI to show a clear advantage over TS in terms of patient
benefit, especially for smaller trials with several arms.
[Figure 3 about here.]
4. Dichotomisation: Patient Benefit and Efficiency Cost
Phase II cancer trials, such as the ones considered above, are traditionally conducted as
single arm studies using a binary response rate as the primary endpoint which is formed by
splitting the underlying continuous data (change in tumour size) into two groups (success
or failure of a treatment), i.e. dichotomising. This dichotomisation is often based on the
Response Evaluation Criteria in Solid Tumors (RECIST) (Eisenhauer et al, 2009) which
categorises the change in tumour size and number of lesions into four levels; complete
response, partial response, stable disease and progressive disease. A treatment is considered
a success if patients experience either a partial or complete response (i.e. at least a 30%
reduction in the total diameter of target lesions), and a failure otherwise. If new lesions
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appear in the patient, or non-target lesions grow beyond a certain percentage, this is also
classed as a treatment failure.
Dichotomising continuous data is a widely adopted approach in clinical research. However,
this comes at the cost of losing power as well as raising issues such as where exactly the
dichotomisation cutpoint should be. Within the literature, there is a strong focus on the loss
of efficiency associated with dichotomising a continuous variable, but no mention of the cost
to patients in the trial. Therefore, we will use the same two-armed example as in Section 3.2
to compare the performance, in terms of patient benefit measures, of the continuous FLGI
to the binary FLGI, as proposed in Villar et al (2015). However, since the binary FLGI
compares response rates, we increase the total sample size from T = 72 to T = 128, as this
is the size required to detect an improvement from 20% to 40% with 80% power using a
one-sided test at the α = 0.05 level; a 77% increase on that required for the continuous case.
Figure 2 shows the results. The efficiency costs are reflected by the power loss associated
with using a binary endpoint rather than a continuous endpoint. A trial of size 128 achieves
almost 100% power to detect the target treatment difference when using a continuous
endpoint, as opposed to 80% power when using a binary one. Moreover, Figure 2 also
illustrates that there is an important patient benefit cost of using a binary endpoint instead
of a continuous one when using a response-adaptive allocation. In particular, the normal
FLGI has not only a higher power level, but also a considerably higher expected proportion
of patients on the best arm for every block size in a trial of size 128.
5. Imputing Complete Responses and Drop-outs
The patient benefit cost associated with dichotomising requires an important practical con-
sideration to be taken into account when interpreting it. Before implementing any response-
adaptive design in practice, particularly in cancer trials like those used in this paper, we need
to propose an online imputation method to account for patients who: (i) die or drop out of
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the trial before the time of follow-up or (ii) have a complete response (since in this case, the
log ratio will be undefined). Two different approaches have been proposed by Karrison et
al (2007) and Jaki et al (2013) to overcome these issues; a review of which is provided by
Wason and Jaki (2016).
In the previous section, we assumed that all patients generate an observable response,
which is clearly not realistic. Whereas deaths/drop-outs and complete responses are easily
imputed in the binary case, there is no obvious way of translating these outcomes into
continuous variables. Therefore, we now introduce a simple suggestion by building upon the
solution provided by Karrison et al (2007). Rather than use the best and worst possible
outcomes for complete responses and deaths/drop-outs, respectively, as in Karrison et al
(2007), we instead randomise from the upper tail of the (theoretical) distribution under
H1 if we observe a complete response, and from the lower tail of the null distribution to
account for deaths or drop-outs, regardless of which treatment the patient received. Thus,
this approach satisfies the requirement of computing the missing values online as the trial
progresses, allowing for a response-adaptive algorithm to be used. Further, choosing the
missing values randomly, as opposed to using the same values every time, as in Karrison
et al (2007), is perhaps a better reflection of reality or, at the very least, a reflection that
matches the theoretical distributional assumptions made in order to find the size of the study
based on power considerations.
Figure 2 shows the results for the normal FLGI when we implement our online imputation
method assuming that we observe a 4% rate of deaths or drop-outs and a 1% rate of complete
responses. These rates are consistent with values reported in Karrison et al (2007). Results
of the FLGI rule for this case are labelled normal FLGI with missing data (MD). Figure 2
shows that, as expected, this missing data assumption decreases both the efficiency and
patient benefit advantages over the FLGI with complete observations. Nevertheless, the
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imputed continuous FLGI procedure continues to outperform the binary FLGI with respect
to both criteria. Figure 3 suggests that similar conclusions also apply for the multi-armed
missing data case.
6. Discussion
The current RAR literature has very few procedures for the case in which the endpoint is
continuous and normally distributed, fewer still that are defined for the multi-armed case
and none that are non-myopic. We propose a RAR algorithm based on the Gittins index
that is applicable to multi-armed trials with a normally distributed endpoint and which is
also near-optimal in terms of patient benefit.
In this paper, we have shown that using a continuous endpoint instead of dichotomising
can offer efficiency but also patient benefit advantages if combined with RAR. Implementing
a RAR procedure, such as the FLGI, in the context of Phase II cancer trials requires dealing
with missing data from patients in an online fashion. The naive imputation method suggested
in this work, based on the method by Karrison et al (2007), shows that there are still
important benefits even if a low rate of missing observations is anticipated. Further work is
needed to develop imputation methods that can be used in combination with RAR.
Although our simulations assume a common and known variance for simplicity of ex-
position, the methods presented in this paper can easily be applied if variances between
treatment arms differ and can also extend to the case in which variances are unknown by
using a different set of index values. Additionally, the method can incorporate covariates in
the way suggested by Villar and Rosenberger (2018).
The motivation of our proposed algorithm is in the setting of clinical trials, but its use is
not limited to medical applications. In particular, the RAR rule also applies to sequential
allocation problems more generally.
A near-optimal RAR procedure for multi-armed clinical trials with normally distributed outcomes 19
7. Supplementary Materials
The codes to replicate simulations and supplementary material is available at the Biometrics
Website.
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aGI1,3 = 1
G1(0,1,1,0.995) = 1.8175
G0(−0.1, 3, 1, 0.995) = 0.8493
aGI0,4 = 1
G1(Y1,3/2, 2, 1, 0.995) < 0.8493
G0(−0.1,3,1,0.995) = 0.8493
0.2318
Y1,3 < −0.7328
aGI1,4 = 1
G1(Y1,3/2,2,1,0.995) > 0.8493
G0(−0.1, 3, 1, 0.995) = 0.84930.7682
Y1,3 >
−0.7328
Figure 1. The FLGI rule and a probability tree of all trial histories using the Gittins
index rule when K + 1 = 2, b = 2, x˜2 = [(−0.1, 3); (0, 1)] and d = 0.995. Bold text indicates
the allocated treatment under the Gittins index rule {aGIk,t}. Notice that for simplicity of the
illustration we have omitted the branch corresponding to the case when Y1,3 = −0.7328 since
P (Y1,3 = −0.7328) = 0.
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Figure 2. The trade-off between the expected proportion of patients allocated to the
superior arm, E(p∗), and power for the: Binary ER, Normal ER, Binary FLGI, Normal
FLGI and Normal FLGI with Missing Data (MD) imputed in an online fashion for block
sizes b = (1, 2, 4, 8, 16, 32, 64, 128) in a trial of size T = 128.
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Figure 3. The trade-offs between the expected proportion of patients allocated to the
superior arm, E(p∗), power, average bias in the treatment effect estimate and variability of
patient allocations for the different designs, including Normal FLGI and Normal FLGI with
Missing Data (MD), for block sizes b = (1, 15, 40, 60) in a trial of size T = 120.
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H0 : µ1 = µ2 = 0.155 H1 : µ1 = 0.155, µ2 = 0.529
Design z1−α α E(p∗) (s.d.) ETO % (s.d.) Bias (s.d.) 1− β E(p∗) (s.d.) ETO % (s.d.) Bias (s.d.)
ER (b = 1) 1.645 0.0503 0.4996 (0.06) -0.54 (5.44) -0.0010 (0.15) 0.7938 0.5004 (0.06) -0.18 (5.67) -0.0010 (0.15)
FLGI (b = 1) 2.000 0.0512 0.4962 (0.33) 0.59 (5.47) 0.0037 (0.48) 0.2273 0.8815 (0.17) 41.99 (7.04) 0.2157 (0.45)
(b = 2) 1.946 0.0530 0.49562 (0.32) -0.45 (5.42) 0.0038 (0.43) 0.2828 0.8796 (0.15) 41.30 (6.82) 0.1849 (0.41)
(b = 4) 1.943 0.0500 0.4966 (0.30) -0.53 (5.42) 0.0064 (0.38) 0.3190 0.8680 (0.15) 39.72 (6.80) 0.1456 (0.35)
(b = 6) 1.902 0.0495 0.4969 (0.29) 1.29 (5.48) 0.0023 (0.34) 0.3639 0.8643 (0.13) 39.89 (6.54) 0.1202 (0.30)
(b = 9) 1.881 0.0455 0.5004 (0.28) 0.32 (5.43) -0.0015 (0.30) 0.4085 0.8494 (0.13) 38.08 (6.44) 0.0855 (0.26)
(b = 12) 1.819 0.0505 0.4992 (0.26) -0.05 (5.42) 0.0000 (0.26) 0.4821 0.8348 (0.13) 36.60 (6.51) 0.0636 (0.23)
(b = 18) 1.795 0.0509 0.4993 (0.24) 0.41 (5.43) 0.0027 (0.23) 0.5456 0.8079 (0.12) 33.59 (6.28) 0.0381 (0.20)
(b = 36) 1.700 0.0499 0.5027 (0.18) 0.05 (5.42) -0.0010 (0.17) 0.7060 0.7130 (0.10) 23.23 (6.00) 0.0077 (0.17)
CGI (c = 2) 1.705 0.0533 0.5046 (0.29) -1.52 (5.32) -0.0034 (0.25) 0.4803 0.8416 (0.12) 34.87 (6.23) 0.0281 (0.21)
MZR (nER = 1, c = 0.2) 1.723 0.0512 0.5015 (0.19) -0.64 (5.42) -0.0017 (0.19) 0.7631 0.6584 (0.12) 17.03 (5.72) 0.0242 (0.17)
(nER = 6, c = 0.2) 1.744 0.0469 0.4991 (0.17) -0.42 (5.40) 0.0003 (0.18) 0.7704 0.6416 (0.09) 15.30 (5.32) 0.0200 (0.16)
(nER = 11, c = 0.2) 1.722 0.0514 0.4999 (0.14) 1.06 (5.43) -0.0010 (0.17) 0.7772 0.6169 (0.08) 13.26 (5.22) 0.0150 (0.16)
TS (b = 1) 1.718 0.0521 0.4993 (0.12) 0.23 (5.45) 0.0035 (0.18) 0.7564 0.7073 (0.11) 22.77 (6.26) 0.0474 (0.22)
(b = 2) 1.735 0.0458 0.5007 (0.12) -0.02 (5.38) -0.0007 (0.17) 0.7488 0.7059 (0.11) 22.51 (6.17) 0.0430 (0.21)
(b = 4) 1.732 0.0485 0.4991 (0.11) -0.07 (5.46) 0.0012 (0.17) 0.7519 0.6996 (0.11) 21.79 (6.24) 0.0393 (0.21)
(b = 6) 1.718 0.0468 0.4991 (0.11) 0.33 (5.50) -0.0002 (0.17) 0.7509 0.6934 (0.11) 21.30 (6.25) 0.0358 (0.20)
(b = 9) 1.696 0.0510 0.4992 (0.11) -0.10 (5.42) 0.0005 (0.17) 0.7660 0.6860 (0.11) 20.29 (6.11) 0.0335 (0.19)
(b = 12) 1.681 0.0516 0.5000 (0.11) 0.22 (5.42) -0.0009 (0.17) 0.7734 0.6781 (0.11) 19.57 (6.20) 0.0311 (0.19)
(b = 18) 1.687 0.0503 0.4989 (0.10) -0.71 (5.42) 0.0011 (0.17) 0.7691 0.6613 (0.11) 17.32 (6.22) 0.0235 (0.18)
(b = 36) 1.645 0.0516 0.5005 (0.08) 0.29 (5.44) -0.0006 (0.16) 0.7879 0.6099 (0.10) 12.15 (6.05) 0.0088 (0.16)
Table 1
Comparison of performance measures for a two-armed trial using different designs when T = 72, averaged over
10,000 trial replications.
